Association of STAT3, CYP3A5 , and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients
Anticancer Research · 2023
DOI: 10.21873/anticanres.16331 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Anticancer Research, 2023. Verfasst von Masaaki Tanda und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Kobe University Hospital, Kobe, Japan. Hauptthemen laut MEDLINE: Aniline Compounds, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Themen: Patientensicherheit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Kobe University Hospital, Kobe, Japan.
- Department of Pharmacy, Kobe University Hospital, Kobe, Japan; yamakz@med.kobe-u.ac.jp.
- Department of Pharmacy, Nara Prefecture General Medical Center, Nara, Japan.
- Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
- Division of Respiratory Medicine, Nara Prefecture General Medical Center, Nara, Japan.
Zitieren
APA
Tanda, M., Yamamoto, K., Hori, T., Nishiguchi, H., Yagi, M., Shimizu, M., Konishi, T., Ozaki, T., Yoshioka, N., Tachihara, M., Ito, T., Ikushima, S., Omura, T., & Yano, I. (2023). Association of STAT3, CYP3A5 , and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients. Anticancer Research. https://doi.org/10.21873/anticanres.16331
Vancouver
Tanda M, Yamamoto K, Hori T, Nishiguchi H, Yagi M, Shimizu M, et al. Association of STAT3, CYP3A5 , and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients. Anticancer Research. 2023. doi:10.21873/anticanres.16331
BibTeX
@article{Tanda2023,
author = {Tanda, Masaaki and Yamamoto, Kazuhiro and Hori, Tomoki and Nishiguchi, Hiroki and Yagi, Miki and Shimizu, Michiko and Konishi, Toru and Ozaki, Tomonori and Yoshioka, Natsue and Tachihara, Motoko and Ito, Takefumi and Ikushima, Shigeki and Omura, Tomohiro and Yano, Ikuko},
title = {Association of STAT3, CYP3A5 , and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16331}
}
EUVIMED